Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Discontinued Operations - Discontinued Operations (Details)

v3.8.0.1
Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Dec. 31, 2016
Accounts and other receivables     $ 1,598,994
Inventory, net     1,374,618
Prepaid expenses     170,635
Assets associated with discontinued operations, current     3,144,247
Property and equipment, net of accumulated depreciation     70,973
Patents and trademarks, net of accumulated amortization     34,282
Assets associated with discontinued operations, noncurrent     105,255
Total assets associated with discontinued operations     3,249,502
Accounts payable 232   232   1,957,938
Accrued liabilities 32,909   32,909   607,659
Deferred revenue     2,300,000
Liabilities associated with discontinued operations, current 33,141   33,141   $ 4,865,597
Lymphoseek sales revenue   $ 6,672,489 2,917,213 $ 14,673,689  
Grant and other revenue   385   575  
Total revenue   6,672,874 2,917,213 14,674,264  
Cost of goods sold   918,928 364,192 2,012,301  
Gross profit   5,753,946 2,553,021 12,661,963  
Research and development (5,951) 356,612 382,070 1,450,231  
Selling, general and administrative   1,129,093 805,464 4,092,951  
Total operating expenses (5,951) 1,485,705 1,187,534 5,543,182  
Income from discontinued operations 5,951 4,268,241 1,365,487 7,118,781  
Interest expense   (2,566,330) (1,718,506) (12,286,093)  
Income (loss) before income taxes 5,951 1,701,911 (353,019) (5,167,312)  
Benefit from (provision for) income taxes (552) 20,181  
Income (loss) from discontinued operations $ 5,399 $ 1,701,911 $ (332,838) $ (5,167,312)